Pharmaceutical

ASCO 2024: Novartis’ Scemblix outperforms standard of care in CML

A Phase III trial with the drug has shown improved molecular response rates compared to standard of care therapies in CML.

Jun 2, 2024 - 04:00
ASCO 2024: Novartis’ Scemblix outperforms standard of care in CML
A Phase III trial with the drug has shown improved molecular response rates compared to standard of care therapies in CML.
Read the original article

Tags:

Previous Article

Key opinion leaders on unmet needs in amyotrophic lateral sclerosis

Next Article

Compound medication pharmacies and companies 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Merck, Johnson & Johnson CEOs agree to testify in Congress on high drug prices, avoiding Bernie Sanders’ subpoena

STAT+: Merck, Johnson & Johnson CEOs agree to testify i...

Jan 26, 2024

FDA approves Moderna’s RSV vaccine mRESVIA

FDA approves Moderna’s RSV vaccine mRESVIA

Jun 4, 2024

FDA will not meet ahead of bluebird bio’s sickle cell disease gene therapy PDUFA date

FDA will not meet ahead of bluebird bio’s sickle cell d...

Aug 16, 2023